217 related articles for article (PubMed ID: 18336603)
21. The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis.
Pappot H; Pedersen AN; Brünner N; Christensen IJ
Lung Cancer; 2006 Feb; 51(2):193-200. PubMed ID: 16325301
[TBL] [Abstract][Full Text] [Related]
22. Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.
Curino A; Patel V; Nielsen BS; Iskander AJ; Ensley JF; Yoo GH; Holsinger FC; Myers JN; El-Nagaar A; Kellman RM; Shillitoe EJ; Molinolo AA; Gutkind JS; Bugge TH
Oral Oncol; 2004 Nov; 40(10):1026-32. PubMed ID: 15509494
[TBL] [Abstract][Full Text] [Related]
23. Type-1 plasminogen activator inhibitor in human renal cell carcinoma.
Wagner SN; Atkinson MJ; Thanner S; Schmitt M; Wilhelm O; Rotter M; Höfler H
J Pathol; 1996 May; 179(1):95-9. PubMed ID: 8691352
[TBL] [Abstract][Full Text] [Related]
24. Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I: novel tumor-derived factors with a high prognostic and predictive impact in breast cancer.
Harbeck N; Kates RE; Gauger K; Willems A; Kiechle M; Magdolen V; Schmitt M
Thromb Haemost; 2004 Mar; 91(3):450-6. PubMed ID: 14983219
[TBL] [Abstract][Full Text] [Related]
25. [u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast].
Harbeck N; Thomssen C
Zentralbl Gynakol; 2003 Sep; 125(9):362-7. PubMed ID: 14569518
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of uPA, PAI-1, and DNA content in adult renal cell carcinoma.
Chautard D; Dalifard I; Chassevent A; Guyetant S; Daver A; Vielle B; Soret JY
Urology; 2004 Jun; 63(6):1055-60. PubMed ID: 15183949
[TBL] [Abstract][Full Text] [Related]
27. [Urokinase and tissue type plasminogen activators and their type-1 inhibitor (PAI-1) in gastric cancer].
Gerstein ES; Shcherbakov AM; Kaz'min AI; Ognerubov NA; Kushlinskiĭ NE
Vopr Onkol; 2003; 49(2):165-9. PubMed ID: 12785198
[TBL] [Abstract][Full Text] [Related]
28. Urokinase plasminogen activator is elevated in human astrocytic gliomas relative to normal adjacent brain.
Kinder DH; Berger MS; Mueller BA; Silber JR
Oncol Res; 1993; 5(10-11):409-14. PubMed ID: 8054701
[TBL] [Abstract][Full Text] [Related]
29. [Vascular endothelial growth factor and plasminogen activators in endometrial carcinoma and hyperplasia].
Gerstein ES; Gritsaenko EV; Shcherbakov ME; Shcherbakov AM; Ognerudov NA; Kushlinskiĭ NE
Vopr Onkol; 2003; 49(6):725-9. PubMed ID: 14976916
[TBL] [Abstract][Full Text] [Related]
30. Complex congenital malformations and the impact of the plasminogen activator system and beta-hCG in amniotic fluid.
Verkleij-Hagoort AC; Ursem NT; Hop WC; Geurts-Moespot A; Steegers EA; Sweep FC; Steegers-Theunissen RP
Eur J Obstet Gynecol Reprod Biol; 2007 Nov; 135(1):47-52. PubMed ID: 17141398
[TBL] [Abstract][Full Text] [Related]
31. Concentrations of plasminogen activators and their inhibitors in blood preconceptionally, during and after pregnancy.
Coolman M; de Groot CJ; Steegers EA; Geurts-Moespot A; Thomas CM; Steegers-Theunissen RP; Sweep FC
Eur J Obstet Gynecol Reprod Biol; 2006; 128(1-2):22-8. PubMed ID: 16584829
[TBL] [Abstract][Full Text] [Related]
32. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
[TBL] [Abstract][Full Text] [Related]
33. Glutathione and glutathione S-transferases as early markers for ovarian carcinomas: case series.
Sprem M; Babić D; Abramić M; Vrhovec I; Skrk J; Milicić D; Ambriović Ristov A; Kalafatić D; Osmak M
Croat Med J; 2001 Dec; 42(6):624-9. PubMed ID: 11740844
[TBL] [Abstract][Full Text] [Related]
34. Plasmin, plasminogen activators and inhibitor in human osteoarthritic cartilage.
Martel-Pelletier J; Faure MP; McCollum R; Mineau F; Cloutier JM; Pelletier JP
J Rheumatol; 1991 Dec; 18(12):1863-71. PubMed ID: 1724464
[TBL] [Abstract][Full Text] [Related]
35. Evidence for the regulation of urokinase and tissue type plasminogen activators by the serpin, protein C inhibitor, in semen and blood plasma.
España F; Estellés A; Fernández PJ; Gilabert J; Sánchez-Cuenca J; Griffin JH
Thromb Haemost; 1993 Dec; 70(6):989-94. PubMed ID: 8165623
[TBL] [Abstract][Full Text] [Related]
36. Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
Warnecke-Eberz U; Prenzel KL; Baldus SE; Metzger R; Dienes HP; Bollschweiler E; Hoelscher AH; Schneider PM
Pancreas; 2008 Mar; 36(2):173-7. PubMed ID: 18376309
[TBL] [Abstract][Full Text] [Related]
37. [The concentration of tissue--type plasminogen activator (t-PA) in extracts of breast cancer tissue].
Ziółkowska E; Pietrusińska E; Łozyńska-Podhrebelna D
Pol Merkur Lekarski; 2008 Dec; 25(150):489-94. PubMed ID: 19205379
[TBL] [Abstract][Full Text] [Related]
38. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
Chu SC; Yang SF; Lue KH; Hsieh YS; Hsiao TY; Lu KH
J Rheumatol; 2006 Feb; 33(2):311-7. PubMed ID: 16465663
[TBL] [Abstract][Full Text] [Related]
39. BIGH3 is overexpressed in clear cell renal cell carcinoma.
Yamanaka M; Kimura F; Kagata Y; Kondoh N; Asano T; Yamamoto M; Hayakawa M
Oncol Rep; 2008 Apr; 19(4):865-74. PubMed ID: 18357369
[TBL] [Abstract][Full Text] [Related]
40. Comparative study of plasminogen activators in cancers and normal mucosae of human urinary bladder.
Hasui Y; Suzumiya J; Marutsuka K; Sumiyoshi A; Hashida S; Ishikawa E
Cancer Res; 1989 Feb; 49(4):1067-70. PubMed ID: 2492205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
